Biostatistics and Clinical Epidemiology Fondazione IRCCS San Gerardo dei Tintori Monza Italy; School of Medicine and Surgery University of Milano Bicocca

Chilean National Pediatric Oncology Group Santiago Chile; Hospital Dr Gustavo Fricke Vina del Mar Chile

Department of Paediatric Oncology Karolinska University Hospital and Department of Women's and Children's Health Karolinska Institutet Stockholm

Department of Pediatric Hemato Oncology University Hospital of Rennes Rennes

Department of Pediatric Hematology and Oncology 2nd Faculty of Medicine Charles University and University Hospital Motol Prague Czech Republic

Department of Pediatric Hematology and Oncology St Anna Children's Hospital Medical University of Vienna Vienna Austria; St Anna Children's Cancer Research Institute Vienna

Division of Cancer Sciences School of Medical Sciences Faculty of Biology Medicine and Health University of Manchester Manchester UK; Tata Translational Cancer Research Centre Tata Medical Center Kolkata

Pediatrics and Tettamanti Center Fondazione IRCCS San Gerardo dei Tintori Monza

Pediatrics and Tettamanti Center Fondazione IRCCS San Gerardo dei Tintori Monza Italy; School of Medicine and Surgery University of Milano Bicocca

Princess Maxima Center for Pediatric Oncology Utrecht

The Chinese University of Hong Kong Hong Kong Children's Hospital

University Medical Center Schleswig Holstein Pediatrics Campus Kiel Kiel

University Medical Centre Hamburg Eppendorf Clinic of Paediatric Haematology and Oncology Hamburg

Zobrazit více v PubMed

Schrappe M, Arico M, Harbott J, et al. . Philadelphia chromosome-positive (Ph+) childhood acute lymphoblastic leukemia: good initial steroid response allows early prediction of a favorable treatment outcome. Blood. 1998;92(8):2730-2741. PubMed

Arico M, Valsecchi MG, Camitta B, et al. . Outcome of treatment in children with Philadelphia chromosome-positive acute lymphoblastic leukemia. N Engl J Med. 2000;342(14):998-1006. PubMed

Arico M, Schrappe M, Hunger SP, et al. . Clinical outcome of children with newly diagnosed Philadelphia chromosomepositive acute lymphoblastic leukemia treated between 1995 and 2005. J Clin Oncol. 2010;28(31):4755-4761. PubMed PMC

Schultz KR, Bowman WP, Aledo A, et al. . Improved early event-free survival with imatinib in Philadelphia chromosome-positive acute lymphoblastic leukemia: a children’s oncology group study. J Clin Oncol. 2009;27(31):5175-5181. PubMed PMC

Schultz KR, Carroll A, Heerema NA, et al. . Long-term follow-up of imatinib in pediatric Philadelphia chromosome-positive acute lymphoblastic leukemia: Children’s Oncology Group study AALL0031. Leukemia. 2014;28(7):1467-1471. PubMed PMC

Slayton WB, Schultz KR, Kairalla JA, et al. . Dasatinib plus intensive chemotherapy in children, adolescents, and young adults with Philadelphia chromosome-positive acute lymphoblastic leukemia: results of Children’s Oncology Group Trial AALL0622. J Clin Oncol. 2018;36(22):2306-2314. PubMed PMC

Hunger SP, Tran TH, Saha V, et al. . Dasatinib with intensive chemotherapy in de novo paediatric Philadelphia chromosomepositive acute lymphoblastic leukaemia (CA180-372/COG AALL1122): a single-arm, multicentre, phase 2 trial. Lancet Haematol. 2023;10(7):e510-e520. PubMed

Biondi A, Schrappe M, De Lorenzo P, et al. . Imatinib after induction for treatment of children and adolescents with Philadelphia-chromosome-positive acute lymphoblastic leukaemia (EsPhALL): a randomised, open-label, intergroup study. Lancet Oncol. 2012;13(9):936-945. PubMed PMC

Biondi A, Cario G, De Lorenzo P, et al. . Long-term follow up of pediatric Philadelphia positive acute lymphoblastic leukemia treated with the EsPhALL2004 study: high white blood cell count at diagnosis is the strongest prognostic factor. Haematologica. 2019;104(1):e13-e16. PubMed PMC

Biondi A, Gandemer V, De Lorenzo P, et al. . Imatinib treatment of paediatric Philadelphia chromosome-positive acute lymphoblastic leukaemia (EsPhALL2010): a prospective, intergroup, open-label, single-arm clinical trial. Lancet Haematol. 2018;5(12):e641-e652. PubMed

Smith M, Arthur D, Camitta B, et al. . Uniform approach to risk classification and treatment assignment for children with acute lymphoblastic leukemia. J Clin Oncol. 1996;14(1):18-24. PubMed

Xie J, Liu C. Adjusted Kaplan-Meier estimator and log-rank test with inverse probability of treatment weighting for survival data. Stat Med. 2005;24(20):3089-3110. PubMed

Vora A, Andreano A, Pui CH, et al. . Influence of cranial radiotherapy on outcome in children with acute lymphoblastic leukemia treated with contemporary therapy. J Clin Oncol. 2016;34(9):919-926. PubMed PMC

Halsey C, Buck G, Richards S, Vargha-Khadem F, Hill F, Gibson B. The impact of therapy for childhood acute lymphoblastic leukaemia on intelligence quotients; results of the risk-stratified randomized central nervous system treatment trial MRC UKALL XI. J Hematol Oncol. 2011;4:42. PubMed PMC

Loning L, Zimmermann M, Reiter A, et al. . Secondary neoplasms subsequent to Berlin-Frankfurt-Munster therapy of acute lymphoblastic leukemia in childhood: significantly lower risk without cranial radiotherapy. Blood. 2000;95(9):2770-2775. PubMed